I'm LongbridgeAI, I can summarize articles.The Week
SKB BIO (6990.HK) fell 9.45% this week to HK$398.40, trailing the Hang Seng Index by 3.8 percentage points (the index lost 5.65%). The stock moved lower across all four trading days, opening Monday at HK$440 and briefly touching HK$443.60 before sliding. It hit a low of HK$395 on Thursday and closed at HK$398.40. Weekly amplitude was 11.05%, with volume running about 9% above the recent daily median.
Key Events
The main company-specific development was a boardroom reshuffling. On 18 November after market close, the company announced a change of chairman of the board and changes to the composition of board committees, alongside a new list of directors and their roles. This is not a product or commercial-stage update, but it landed with the stock already down from a late-August high of HK$535.50 to the HK$400 area. Sector-wise, Monday’s midday session saw AI computing stocks plunge broadly, though the direct read-across to this name was limited.
Analyst Ratings
Among 21 institutions covering SKB BIO, 17 rate it buy, 3 rate it outperform, and 1 rates it hold; none rate it underperform or sell. The consensus rating is strong buy. The consensus target price sits at HK$617.60, about 55% above the current price, with a target range of HK$520 to HK$765.30. The stock ranks third within the biotechnology sector’s 52 comparable names.
The Week Ahead
Third-quarter fiscal 2026 results are due after the close on 25 November. The background to this week’s chairman change and the implementation of the new committee structure may get more colour on the earnings call or in the accompanying materials. With the stock now back in the HK$395–400 band, near the 2 November range low of HK$392.40, the commercial update and fiscal 2027 guidance will be the next data points to test after this week’s slide.
In Short
The tension this week: a strong-buy consensus rating and a HK$617.60 consensus target versus a near-9.5% weekly drop that has left the stock close to the bottom of its 60-day range. Latest-day flow showed large-lot money as a net seller, though that is a single-day snapshot rather than a weekly cumulative figure. Valuation sits at a high 546.98x P/E and 15.5x P/B. The 25 November quarterly report is the next event that could either anchor or extend the downtrend.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
